|
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc.
(OTCBB:PLRS -
News;
DAX:PJT), a bio-therapeutics Company dedicated to the commercialization
of unrelated donor-patient (allogeneic) cell therapy products for a variety of
malignant, degenerative and auto-immune indications, announced today
that it will present favorable results of pre-clinical studies of its
proprietary PLacental eXpanded (PLX) cells for additional clinical
indications on October 18th, at the "3rd World Congress on Regenerative
Medicine" in Leipzig, Germany.
The Company previously announced that it had obtained favorable
results in pre-clinical testing of PLX cells to treat limb ischemia, a
potential market of over $1 Billion. PLX cells also showed in vitro to
have properties that the Company believes gives these cells the
potential to treat Parkinson's Disease.
Mr. Zami Aberman, Pluristem Chairman and CEO commented, "We are very
proud that the Congress' organizing committee found our research and
studies valuable and chose Pluristem to present its findings at the
Congress. We strongly believe that our PLX cells can be used to treat
other diseases, such as central nervous system and cardiovascular
disorders. We will soon submit the IND for our first product, PLX-BMT, for
the treatment of blood cancers, to begin clinical trials early next year
in the USA."
About the "3rd World Congress on Regenerative Medicine"
On October 18-20, 2007 in Leipzig, Germany, the 3rd World Congress on
Regenerative Medicine (WCRM), internationally renowned scientists from
several countries will present the newest results of their research.
Stem cells, umbilical cord cells, bone and cartilage regeneration,
immunology, skin and tissue regeneration as well as tissue engineering,
bioreactors and imaging are themes for plenary lectures and it is
expected that fruitful discussions and a general exchange of experience
will take place between science and industry. The Congress is organized
by the Fraunhofer Institute for Cell Therapy and Immunology.
Additionally, the World Congress is accompanied by an extensive
industrial trade fair, which makes direct communication possible between
representatives from science and industry.
http://www.regmed.org/general/leipzig.php
About Pluristem
Pluristem Life Systems, Inc. is a Company dedicated to the
commercialization of unrelated donor-patient (allogeneic) stem cell therapy
products for the treatment of numerous severe degenerative, malignant
and autoimmune disorders. The Company's first planned product, PLX-BMT,
targets a $2 billion market and is intended to resolve the global
shortfall of matched tissue for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem cells (HSCs) contained
in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells (MSCs)
obtained from the placenta and expanded in the Company's proprietary
PluriX(TM) 3D bioreactor that imitates the natural microstructure of
bone marrow and does not require supplemental growth factors, cytokines
or other exogenous materials. Pluristem believes the resultant expanded
cells, termed PLX cells, are multipotent and able to differentiate into
a variety of cell types as well as being immune-privileged to protect
the recipient from immunological reactions that often accompanies
transplantation. Pluristem believes their future products will
participate in the approximate $30 billion therapeutic and regenerative
cellular market.
Pluristem has offices in the USA with research and manufacturing
facilities in Israel.
www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include that
PLX-BMT targets a $2 billion market and is intended to resolve the global
shortfall of matched tissue for bone marrow transplantation (BMT); that
we will present favorable results of pre-clinical studies; that our PLX
cells can be used to treat other diseases; that we will soon submit the
IND for our first product, PLX-BMT; that future Pluristem products will
participate in the approximate $30 billion therapeutic and regenerative
cellular market. Factors that could prevent our forward looking
statements from being achieved include that we may be unable to get
regulatory approval for our products; we may be unsuccessful in
developing any products; our technology may not be validated as we
progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose
knowledge is essential to the development of our products; unforeseen
scientific difficulties may develop with our process; results in the
laboratory may not translate to equally good results in real surgical
settings; our patents may not be sufficient to protect essential aspects
of our technology; competitors may invent better technology; our
products may not work as well as hoped or worse, our products may harm
recipients; and we may not be able to raise funds for development or
working capital when we require it. As well, our products may never
develop into useful products and even if they do, they may not be
approved for sale to the public. For further risk factors see the
Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com . |
